Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
NCT07566897Phase 1Not yet recruiting
- Sponsor
- Philogen
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of darleukin in renal cell carcinoma (RCC), pancreatic adenocarcinoma (PDAC) and colorectal adenocarcinoma (3 arms), sponsored by Philogen. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 1 year and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
darleukin
03
Conditions
renal cell carcinoma (RCC)pancreatic adenocarcinoma (PDAC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07566897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566897.